# ðŸ©º Clinical Relevance & Applications of EEG Source Localization

> **Goal:** Use source imaging (ESI) to inform diagnosis, prognosis, targeting, and monitoringâ€”while quantifying uncertainty and aligning with clinical endpoints.

---

## 1) Clinical Useâ€‘Cases & Decision Pathways

### 1.1 Ischemic/Hemorrhagic Stroke

**Questions**

* Where is functional disruption? How asymmetric is activity? What predicts recovery?

**Quantitative markers (sourceâ€‘space)**

* **Relative band power maps:** â†‘delta/Î¸, â†“alpha over periâ€‘lesional cortex.
* **DAR / DTABR:** $\mathrm{DAR} = P_\delta / P_\alpha$, $\mathrm{DTABR} = (P_\delta+P_\theta)/(P_\alpha+P_\beta)$.
* **Brain Symmetry Index (BSI)** (hemispheric asymmetry) â€” compute on parcel pairs in source space:

  $$
  \mathrm{BSI}(f) = \frac{\sum_{r\in \text{LH}}|S_r(f)-S_{\pi(r)}(f)|}{\sum_{r\in \text{LH}}(S_r(f)+S_{\pi(r)}(f))}
  $$

  where $\pi(r)$ maps LH parcel to its RH counterpart.

**Workflow**

1. Resting EEG (EC/EO), robust preprocessing.
2. Distributed inverse (sLORETA/eLORETA or wMNE) on subjectâ€‘specific 4â€‘shell models.
3. Parcel time series (Desikan/Destrieux), compute DAR/DTABR & BSI; compare to normative database (zâ€‘scores).
4. Prognosis models: regress NIHSS/modified Rankin at 3 months vs early sourceâ€‘space metrics; report CIs.

**Impact**

* Early **severity/prognosis**, guiding intensity of rehab; mapping **functional diaschisis** beyond structural lesion.

---

### 1.2 Epilepsy (Presurgical Evaluation)

**Questions**

* Where is the irritative zone (interictal spikes)? Does it concord with MRI/PET/SPECT/iEEG? Can ESI guide electrodes and resection?

**Signals & methods**

* **Interictal spikes/fast ripples**: timeâ€‘locked averaging; beamformers for narrowband oscillations; distributed inverses for spikes.
* **Dipole fitting** for early spike peak (focal cases); **MxNE/sparse Bayesian** for multifocal patterns.
* Source localization error typically reported as distance (mm) to iEEG onset or resection margin.

**Workflow**

1. Highâ€‘density EEG (128â€“256), spike detection â†’ average spikes near 50% upstroke.
2. Build 4â€‘shell BEM/FEM; digitized electrodes; average reference or REST.
3. Inverse (eLORETA/wMNE for maps; ECD for focal peak; MxNE for sparse multiple foci).
4. Concordance analysis with MRI lesion, PET hypometabolism, SISCOM/ESI overlays.
5. **Decision aid**: recommend stereoâ€‘EEG (sEEG) contacts targeting ESI maxima; compute distances postâ€‘hoc.

**Impact**

* Higher **localization concordance** â†’ improved selection of sEEG targets; potential **Engel I** seizureâ€‘freedom predictors when resection overlaps ESI maxima.

---

### 1.3 Neurodegeneration (Alzheimerâ€™s & related disorders)

**Questions**

* Are there early functional changes? Can we track progression/therapy?

**Markers**

* **Alpha slowing** (reduced IAF), â†‘theta/delta in posterior networks, defaultâ€‘mode connectivity disruptions.
* Sourceâ€‘space **network metrics** (e.g., wPLI within DMN; posterior alpha power zâ€‘scores vs ageâ€‘matched norms).

**Workflow**

* Eyesâ€‘closed rest â†’ eLORETA/wMNE â†’ Schaeferâ€‘200 parcellation â†’ wPLI (8â€“12â€¯Hz) and aperiodicâ€‘adjusted alpha power â†’ zâ€‘scored summary.

**Impact**

* **Early detection/monitoring** adjunct; not standalone diagnosticâ€”combine with cognitive tests and imaging.

---

### 1.4 Psychiatric Disorders (Depression, Anxiety)

**Questions**

* Biomarkers for stratification and monitoring? Neuromodulation targets?

**Markers (caveats)**

* **Frontal alpha asymmetry** (controversial as a diagnostic marker; treat as *monitoring* candidate).
* Taskâ€‘ or symptomâ€‘relevant **network changes** (e.g., frontoâ€‘limbic coupling).

**Workflow**

* Task or rest; leakageâ€‘robust FC (wPLI/orthogonalized AEC).
* For TMS targeting, identify **hypo/hyperâ€‘connected parcels** (e.g., left DLPFC network coupling) and coâ€‘register to neuronavigation space.

**Impact**

* **Treatment monitoring** (e.g., rTMS response trajectories) more defensible than diagnosis.

---

### 1.5 ADHD

**Notes**

* Theta/beta ratio (TBR) is **nonâ€‘specific**; prefer taskâ€‘relevant source maps (e.g., midline theta during cognitive control) and **connectivity** within attention networks; use as **supportive** evidence only.

---

### 1.6 Schizophrenia & Autism Spectrum Disorders

**Signals**

* **Gamma deficits** (E/I imbalance hypotheses), **MMN/ERN** ERP source alterations, longâ€‘range dysconnectivity.

**Workflow**

* Taskâ€‘locked ERPs (MMN/oddball) â†’ source timeâ€‘courses in auditory/ACC; resting gamma with muscular controls (CSD + stringent artifact rejection).
* Interpret gamma cautiously at scalp; prefer taskâ€‘locked narrowband patterns.

---

## 2) Realâ€‘Time Monitoring & Neurofeedback/BCI

**Latency budget (target â‰¤100â€¯ms endâ€‘toâ€‘end; ideal â‰¤50â€¯ms)**

* Acquisition (buffering): 20â€“40â€¯ms (e.g., 64â€“128â€¯Hz hop on 256â€“512â€¯Hz stream).
* Preprocessing: 5â€“15â€¯ms (causal filters, artifact regressors).
* Inverse: 2â€“10â€¯ms (precomputed $\mathbf{K}$Ã—vector; or fast beamformer).
* Decoding/feedback rendering: 5â€“20â€¯ms.

**Design**

* Fix inverse operator ($\mathbf{K}$) for the session; **precompute** parcel projection; operate on **envelopes** for robustness; apply **leakageâ€‘robust** features (orthogonalized envelopes / wPLI on sliding windows).
* For neurofeedback: choose **one parcel** (or network score) and a **clear shaping rule** (e.g., increase alpha ERS in occipital parcels).

**Useâ€‘cases**

* Stroke rehab (motor imagery â†’ ipsilesional SM parcels).
* Anxiety modulation (posterior alpha upâ€‘training).
* Epilepsy closedâ€‘loop warning (risk indices from sourceâ€‘space features; caution: clinicalâ€‘grade devices require regulatory clearance).

---

## 3) Which Inverse Method When?

| Indication                  | Signal          | Recommended inverse                 | Rationale                                                |
| --------------------------- | --------------- | ----------------------------------- | -------------------------------------------------------- |
| Interictal spikes (focal)   | Transient spike | **ECD** Â± eLORETA                   | Peak localization; simple interpretability               |
| Multifocal/uncertain spikes | Transient       | **eLORETA / MxNE**                  | Balanced localization + focality                         |
| Resting stroke mapping      | Band power      | **eLORETA / wMNE**                  | Stable distributed maps for hemispheric indices          |
| Task ERPs                   | Evoked          | **MNE/dSPM/eLORETA**                | Good timeâ€‘course fidelity                                |
| Narrowband oscillations     | Ongoing         | **LCMV/DICS**                       | Adaptive suppression of interferers (beware correlation) |
| FC/connectivity             | Ongoing/ERP     | **eLORETA/MNE + leakageâ€‘robust FC** | Stable source signals first, then robust FC              |

---

## 4) Reporting & Interpretation (Clinicalâ€‘grade)

**Minimum report items**

* Acquisition (density, montage), preprocessing (filters, artifact removal), **head model** (shells, conductivities), electrode digitization method, **reference**, noise covariance (whitening).
* Inverse method + hyperparameters (depth/loose/orientation, $\lambda$).
* Atlas & space; leakage control in FC.
* **Uncertainty**: PSF width at peak parcel; distance to confidence isosurface; for epilepsy, **distance to resection/onset zone**.
* **Concordance** with MRI/PET/SPECT/iEEG; discrepancies explained.

**Visualization**

* Source maxima on the individual MRI; parcel summaries with zâ€‘scores; FC matrices with densityâ€‘matched graphs.

---

## 5) Validation Against Clinical Endpoints

* **Epilepsy**: distance (mm) between ESI maxima and iEEG onset / resection; association with Engel I outcomes.
* **Stroke**: sourceâ€‘space DAR/DTABR/BSI vs NIHSS/Rankin at discharge and 3â€‘month followâ€‘up.
* **Neurodegeneration**: longitudinal effect sizes in posterior alpha power/IAF & DMN wPLI vs cognitive decline scales (MMSE/MoCA).
* **Psychiatry**: preâ€‘ to postâ€‘treatment changes in network metrics vs clinical scales (HAMâ€‘D, BDI); emphasize *monitoring*, not diagnostic claims.

**Statistical hygiene**

* Multipleâ€‘comparisons control (cluster/TFCE, FDR).
* Testâ€“retest reliability (ICC) for resting measures.
* External validation across sites/hardware when possible.

---

## 6) Safety, Ethics, and Regulatory Notes

* **Device class** & claims: diagnostic vs adjunctive vs researchâ€”match documentation accordingly.
* **Bias & generalization**: site/montage differences; use harmonization (e.g., ComBat) for group analyses.
* **Data privacy**: deâ€‘identify MRIs and EEG; manage PHI in DICOMs.
* **Clinical responsibility**: ESI **augments** but does not replace clinical judgment or imaging.

---

## 7) Practical Pipelines (by Indication)

### 7.1 Epilepsy (interictal)

1. Detect spikes â†’ average; prune artifacts.
2. 4â€‘shell head model + digitized electrodes.
3. eLORETA map at spike peak Â±10â€¯ms; **ECD** fit for peak vertex; optional **MxNE** over spike window.
4. Concordance table with MRI/PET/iEEG; distances; suggestion for sEEG targets.

### 7.2 Stroke (rest)

1. 5â€“10â€¯min EO/EC rest; robust preprocessing.
2. eLORETA/wMNE; parcel extraction (Desikan).
3. Compute DAR, DTABR, IAF; **BSI** on matched parcels.
4. Normative zâ€‘scores; lateralization indices; prognosis model with CI.

### 7.3 Neurofeedback/BCI

1. Precompute $\mathbf{K}$ and parcel projector.
2. Causal filters; envelope extraction; leakageâ€‘robust feature.
3. Latency monitor; feedback display; sessionâ€‘wise QA.

---

## 8) Common Pitfalls & Guardrails

* **Assuming diagnostic specificity** (e.g., TBR for ADHD) â†’ treat as *supportive*, not definitive.
* **Ignoring headâ€‘model uncertainty** â†’ run sensitivity analysis (Â±50% skull Ïƒ) and acknowledge in the report.
* **Sensorâ€‘space FC** reported as sourceâ€‘space â†’ always compute in source space with leakage control.
* **Unwhitened inverses** â†’ inflated false positives in standardized maps.
* **Overâ€‘smoothing & overâ€‘parcellation** â†’ unstable metrics; match resolution to SNR/sensors.

---

## 9) Suggested Figures (for slides/reports)

1. **Epilepsy case**: spike topography â†’ eLORETA map â†’ ECD dot â†’ sEEG plan â†’ resection overlap.
2. **Stroke**: sourceâ€‘space DAR and BSI hemispheric maps with NIHSS scatter.
3. **Neurodegeneration**: posterior alpha power zâ€‘map + IAF shift over time.
4. **Neurofeedback**: latency breakdown bar + online parcel trace.

---

## 10) References & Resources (selected)

**Stroke / qEEG**

* Finnigan, S., & van Putten, M. (2013). qEEG in ischemic stroke. *Clin Neurophysiol*, 124, 10â€“19.

**Epilepsy / ESI**

* Michel, C. M., & Murray, M. M. (2012). EEG as a brain imaging tool. *NeuroImage*, 61, 371â€“385.
* Plummer, C., etâ€¯al. (2019). EEG source imaging in presurgical evaluation: a review. *Clin Neurophysiol*.
* solutions using HDâ€‘EEG and combined modalities (PET/SPECT/iEEG) â€” various clinical series.

**Neurodegeneration**

* Babiloni, C., etâ€¯al. (2020). EEG biomarkers in AD. *Neurobiol Aging*, 85, 1â€“10.

**General / Methods**

* Niedermeyer & Lopes da Silva (2017). *Electroencephalography* (7th ed.). OUP.
* Michel, C. & Brunet, D. (2019). EEG source imaging: a practical review. *Handbook of Clinical Neurology*.

**Societies / Guidance**

* ACNS â€” [https://www.acns.org/](https://www.acns.org/)
* IFCN â€” [https://www.ifcn.info/](https://www.ifcn.info/)

---

### Instructor Notes (optional)

* **Caseâ€‘based workshop:** provide deâ€‘identified epilepsy and stroke datasets; students produce ESI reports with uncertainty, concordance analysis, and clinical decision suggestions.
* **Validation lab:** compute localization error to sEEG/radiology ground truth and evaluate ROC for regionâ€‘level detection.
* **Realâ€‘time lab:** implement a 50â€¯msâ€‘latency neurofeedback loop using precomputed $\mathbf{K}$ and parcel envelopes; measure endâ€‘toâ€‘end latency.
